NCT04239027 - A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration | Biotech Hunter

Enrollment

210

Participants

Timeline

Start Date

January 26, 2021

Primary Completion Date

May 23, 2022

Study Completion Date

February 2, 2023

Conditions

Neovascular Age Related Macular Degeneration

Interventions

DRUG

RTH258/Brolucizumab

"Brolucizumab is a new generation of anti-VEGF (vascular endothelial growth factor). All patients were treated with brolucizumab 6mg: 3 loading injections (at Screening/Baseline, Week 4 and Week 8), followed by maintenance treatment every 8 weeks (Q8W) or every 12 weeks (Q12W) depending on disease activity from Week 16/Week20 to Week 40/Week 44.~Brolucizumab was administered by an intravitreal (IVT) injection to the study. eye."

Trial Locations (40)

13090

Novartis Investigative Site, Aix-en-Provence

14000

Novartis Investigative Site, Caen

14033

Novartis Investigative Site, Caen

17019

Novartis Investigative Site, La Rochelle

17140

Novartis Investigative Site, Lagord

17200

Novartis Investigative Site, Royan

21034

Novartis Investigative Site, Dijon

22190

Novartis Investigative Site, Plérin

31059

Novartis Investigative Site, Toulouse

33000

Novartis Investigative Site, Bordeaux

33270

Novartis Investigative Site, Floirac

34000

Novartis Investigative Site, Montpellier

35033

Novartis Investigative Site, Rennes

37540

Novartis Investigative Site, Saint-Cyr-sur-Loire

38000

Novartis Investigative Site, Grenoble

44093

Novartis Investigative Site, Nantes

44300

Novartis Investigative Site, Nantes

44819

Novartis Investigative Site, Saint-Herblain

45200

Novartis Investigative Site, Montargis

49044

Novartis Investigative Site, Angers

50300

Novartis Investigative Site, Saint-Martin-des-Champs

59000

Novartis Investigative Site, Lille

62321

Novartis Investigative Site, Boulogne-sur-Mer

66000

Novartis Investigative Site, Perpignan

67000

Novartis Investigative Site, Strasbourg

68070

Novartis Investigative Site, Mulhouse

69002

Novartis Investigative Site, Lyon

69317

Novartis Investigative Site, Lyon

75007

Novartis Investigative Site, Paris

75010

Novartis Investigative Site, Paris

76100

Novartis Investigative Site, Rouen

78157

Novartis Investigative Site, Le Chesnay

82000

Novartis Investigative Site, Montauban

84000

Novartis Investigative Site, Avignon

86021

Novartis Investigative Site, Poitiers

92500

Novartis Investigative Site, Rueil-Malmaison

93009

Novartis Investigative Site, Bobigny

94000

Novartis Investigative Site, Créteil

06001

Novartis Investigative Site, Nice

F 13008

Novartis Investigative Site, Marseille